Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer

Prospective Cohort Study Comparing Robotic and Open Surgery for Pancreatic Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04211948

Enrollment

300

Registered

2019-12-26

Start date

2019-03-01

Completion date

2024-12-31

Last updated

2021-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimally Invasive Surgery, Pancreatic Ductal Adenocarcinoma

Keywords

Robotic assisted surgery

Brief summary

The purpose of this study is to determine whether robotic surgery has limitations in terms of patient age, tumor size, location, and vascular relationship when compared to open surgery for pancreatic cancer. Whether robotic surgery has advantages over intraoperative bleeding, operative time, postoperative complications (bleeding, infection, pancreatic fistula) and postoperative hospital stays compared to open surgery.And the differences in lymph nodes harvest and postoperative survival between two groups.

Interventions

PROCEDURErobotic surgery

Pancreatectomy with robotic assisted system

PROCEDUREopen surgery

Traditional open pancreatectomy

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diagnosed pancreatic ductal adenocarcinoma * Patients and their families volunteered to test and signed informed consent.

Exclusion criteria

* Preoperative exclusion: 1. Patients with metastasis (M1) 2. Patients with tumor recurrence 3. Patients with artery and/or vein invasion and can't perform radical resection and reconstruction 4. Patients with poor cardiopulmonary function cannot tolerate surgery; 5. receive neoadjuvant radiotherapy and chemotherapy before surgery; 6. The patient or family member refuses to join the group; 7. Pregnant patients * Intraoperative exclusion: 1. Intraoperative exploration of metastases in other parts besides the primary lesion 2. Other organs malignant tumors metastasize to the pancreas * Postoperative exclusion: 1. pathology confirmed non-pancreatic ductal adenocarcinoma

Design outcomes

Primary

Measure	Time frame
1 year overall survival rate	1 year post-operation
3 years overall survival rate	3 years post-operation

Secondary

Measure	Time frame	Description
Postoperative Complications	Within 90 days or before discharge	pancreatic fistula, bile leakage, hemorrhage, DGE, etc
1, 3years disease free survival rate	1,3years post-operation	—

Countries

China

Contacts

Primary ContactKai Qin, Doctor

qinkai310@sina.com0086-(0)21-64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026